This study is being conducted to assess the long-term safety, tolerability, and efficacy of
sotatercept in PAH.
The aim of this study was to try to reduce the required dose of etomidate used in anesthesia
for upper endoscopy and colonoscopy in critically ill cardiac patients who complain of severe
anemia in cardiac intensive care units by using a low dose of ketamine, which helps to reduce
the side effects of etomidate, the most important of which is its suppressive effect on the
adrenal gland and the secretion of cortisol in such critical cases, while maintaining
hemodynamic stability, and the patient's satisfaction.
Pulmonary hypertension (PH) is a disorder of high blood pressure that impacts the heart and
lungs. Approximately, 50% of individuals with PH experience anxiety or panic disorders. There
is limited evidence on psychological treatments for anxiety in PH; however, results support
the use of Cognitive Behavioural Therapy (CBT). Despite the prevalence and impact of anxiety
in PH; there are no widely available and/or disease specific pathways, thus highlighting an
unmet need in this population. This project aims to develop and pilot, using randomised
control trial methodology, a self-management intervention for individuals with PH based on
The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil
compared to placebo in improving exercise ability as measured by change from baseline in
6-Minute Walk Distance (6MWD) following 12 weeks of active treatment in participants with
This single-arm, Phase 3, 2-part, open-label, multicenter study aims to demonstrate the
safety and tolerability of L606 in patients with PAH switching from a stable Tyvaso dose. The
study will determine the short-term and long-term safety and tolerability of L606 in this
patient population; also evaluate the steady-state pharmacokinetics (PK) of L606 as compared
to Tyvaso, effects on exercise ability, quality of life, and treatment satisfaction with L606
in patients with PAH.
Arrhythmias are considered a prominent phenomenon in pulmonary hypertension (PH) as the
disease progresses. According primarily to retrospective studies with up to 24 hours of
monitoring, supraventricular tachycardias (SVT) can be found in 8-35% of patients, with
significant impact on survival.
Furthermore, a few prospective studies to date deploying short-term monitoring (10 minutes-24
hours) have revealed lower heart rate variability (HRV) in patients with pulmonary arterial
In ASPIRE arrhythmias and heart rate variability is being assessed via long term monitoring.
What problems limit patients' response to exercise? Using exercise cardiac magnetic resonance
imaging to assess the heart's response, with simultaneous measurement of respiratory oxygen
and carbon dioxide levels to assess the lung and skeletal muscle responses, to identify the
rate-limiting factors affecting different types of patient
Occurrence of acute right heart failure (ARHF) remains common during pulmonary hypertension
(PH). Right atrial pressure (RAP) invasive measurement is the gold standard to diagnose ARHF
in order to improve diuretic treatment management. Existence of indirect signs of ARHF on
venous Doppler ultrasound waveform has long been described, but correlation with RAP has not
been properly established yet. It is the aim of our study in order to obtain an additional
tool to manage ARHF.
This is a prospective pilot study to assess the plasma levels of particular proteins involved
in the transforming growth factor beta (TGF-β) pathway and its down stream regulators, CHIP,
as well as micro RNA molecules in subjects with pulmonary arterial hypertension (PAH) and
compare them to control subjects without PAH to see if they can be used as a diagnostic or
prognostic marker of PAH and how this compares to other diagnostic biomarkers N-terminal
pro-natriuretic peptide (NT Pro-BNP) and C-reactive protein (CRP).
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of
ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or
PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.